enVVeno Medical Corporation (NASDAQ:NVNO) confirmed that it has met Nasdaq’s $1.00 per‑share bid‑price rule for the last ten consecutive business days, a milestone that keeps the company’s shares listed on the Nasdaq Capital Market. The compliance was achieved after the company’s stock closed at or above $1.00 from January 20 through February 2, 2026, following a 1‑for‑35 reverse stock split that took effect on January 20.
The reverse split was a strategic move to lift the share price above the Nasdaq threshold after a period of volatility that saw the stock dip below $1.00. The split consolidated 35 shares into one, effectively multiplying the share price by 35 and restoring the minimum bid‑price requirement. The price decline that prompted the split was driven by a combination of weak demand for the company’s clinical‑stage products and a regulatory setback that dampened investor sentiment.
Financially, enVVeno remains a pre‑revenue, loss‑making company. As of December 31 2025, it held approximately $28 million in cash and investments, a cushion that must support ongoing clinical trials and regulatory submissions. The company’s fiscal‑year 2024 results showed a net loss of $21.8 million, and Q3 2025 reported a loss of $4.5 million, underscoring the cash burn that will continue until a product reaches commercialization.
Regulatory challenges persist. In November 2025, the FDA denied an appeal for the VenoValve, a key product in the company’s pipeline, which has delayed the expected commercialization timeline. The company’s other product, enVVe, remains in late‑stage development, but the unfavorable FDA decision highlights the high risk of regulatory approval for its portfolio.
CEO Robert Berman emphasized that the reverse split is “an important first step in a multi‑part plan for 2026 that we expect will create value for shareholders and reestablish our roadmap for enVVeno medical to become the preeminent company for treating deep venous disease.” He added that regaining Nasdaq compliance positions the company to execute its strategic plans and secure future capital markets access.
While the compliance announcement removes the immediate threat of delisting, investors should note that the company still faces significant headwinds: ongoing cash burn, a pre‑revenue business model, and regulatory uncertainty. The Nasdaq listing, however, preserves liquidity and confidence, which are critical for a clinical‑stage medical device firm seeking to fund its next milestones.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.